Skip to main content
OSUR
NASDAQ Industrial Applications And Services

OraSure Q3 Revenue Up 14% to $30.9M; Signs $13M Syntron/True Merger

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$3.53
Mkt Cap
$243.459M
52W Low
$2.08
52W High
$4.58
52W Position info
70% above low
Off High info
23% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

OSUR sits 70% above its 52-week low of $2.08.

Summary

OraSure grew Q3 revenue 14% to $30.9 million with a 45.2% gross margin but still lost $13.1 million, and disclosed a same-day definitive agreement to acquire Syntron Bioresearch and True Diagnostics for $13.0 million upfront plus revenue-based earnouts.


Key Events · Earnings and Guidance · OSUR

  • Q3 Revenue Up 14% to $30.9M

    Total net revenues rose to $30.9 million from $27.1 million a year earlier, with Diagnostics up 16% to $16.8 million and Sample Management Solutions up 21% to $12.5 million.

  • Loss Persists at $13.1M

    GAAP net loss was $13.1 million, or $0.19 per diluted share, versus $13.7 million a year ago; gross margin improved to 45.2% from 43.5%.

  • $13M Syntron/True Merger Signed

    On November 9, 2026 the company signed a definitive agreement for Syntron Bioresearch and True Diagnostics to become wholly-owned subsidiaries, with an aggregate upfront purchase price of $13.0 million in cash plus contingent consideration based on revenue targets through December 31, 2031; closing is expected in Q4 2026.

  • CT/NG Filing Withdrawn, $22.5M Non-Cash Gain

    The July 2026 withdrawal of the CT/NG 510(k) eliminated the milestone contingent consideration and cut the royalty liability, producing a $22.5 million non-cash reduction in the nine-month period — an accounting benefit, not cash.


Analysis · OSUR · Industrial Applications And Services

Revenue growth and margin expansion are real, but the bigger news buried in this 10-Q is the November 9 definitive agreement to buy Syntron Bioresearch and True Diagnostics for $13.0 million upfront in cash, plus earnouts tied to revenue through 2031 — a bolt-on that will be funded from a cash pile that already fell to $148.2 million from $199.3 million this year. The quarter itself: revenue of $30.9 million, up 14%, gross margin 45.2% versus 43.5%, and a net loss of $13.1 million, or $0.19 per share, roughly flat with a year ago. The nine-month loss of $29.2 million looks much better than last year's $49.4 million only because of a $22.5 million non-cash reduction in contingent consideration after the company withdrew its CT/NG 510(k) in July 2026 — that is an accounting gain, not cash, and it also means the CT/NG product is further away than the deal terms assumed. Cash burn of $34.7 million over nine months against $148.2 million on hand leaves roughly three-plus years of runway at the current pace, before the new acquisition. The NowDiagnostics trade-secret case was resolved October 27, 2026 with a permanent injunction in OraSure's favor and all claims dismissed with prejudice, removing a legal overhang.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, OSUR was trading at $3.53 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $243.5M. The 52-week trading range was $2.08 to $4.58. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OSUR - Latest Insights

OSUR
Nov 09, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $3.50
Real-time Price: $3.53 info
Change: +$0.030 (+0.86%) info
Market Cap: $243.459M info
OSUR
Sep 17, 2026, 8:08 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $3.49
Real-time Price: $3.53 info
Change: +$0.040 (+1%) info
Market Cap: $243.459M info
OSUR
Aug 05, 2026, 4:54 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.15
Real-time Price: $3.53 info
Change: -$0.620 (-15%) info
Market Cap: $243.459M info
OSUR
Jul 21, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.93
Real-time Price: $3.53 info
Change: -$0.400 (-10%) info
Market Cap: $243.459M info
OSUR
Jun 11, 2026, 9:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.11
Real-time Price: $3.53 info
Change: -$0.580 (-14%) info
Market Cap: $243.459M info